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The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test
Abstract:
Purpose: To determine the utility of a post-mortem 95 cardiac gene panel in the diverse NYC
population through examining the positive phenotypic predictors of clinically actionable gene
variants as in those with sudden death.
Methods: 254 participants with sudden death underwent post-mortem testing through a 95
cardiac gene panel between Oct 2015-Feb 2018. NGS and variant interpretation was performed
internally at the NYC Office of the Chief Medical Examiner (OCME) following ACMG
guidelines. Medical information was collected from the OCME internal records. Chi-square tests
were used to investigate categorical predictors of pathogenic genetic test results.
Results: Of 319 genetic test results, 51.4% (n = 164) were VUS, 9.1% (n = 29) were clinically
actionable, and 39.5% (n = 126) were negative. Clinically actionable variants were found in 51
of the 95 genes sequenced. Positive predictors of pathogenic genetic test results were significant
personal medical history, significant family history, and heart findings on autopsy.
Conclusion: The results support widespread testing on all sudden death cases, however, this may
not be feasible everywhere due to limited resource or financial allocations. From this study we
were able to determine inclusion criteria for post-mortem genetic testing for heritable cardiac
conditions.
Key Words: post-mortem; genetic test; genetics; cardiac genes; sudden death
Introduction
In the state of New York, a medical examination in the form of an autopsy can be
performed on any death which appears to be the result of an act of violence, unlawful, or
suspicious circumstances, a death of any person confined in a public institution other than a
hospital, infirmary, or nursing home, and any death such that no cause of death can be identified
by a physician (N.Y. County Law § 673). The purpose of these autopsies is to determine the
cause of death for legal and public health purposes, and for closure for the family. During this
time, the medical examiner can perform any tests that are deemed necessary to determine the
cause of death (CDC, 2014). The determination of sudden unexplained death (SUD) as the cause
of death upon autopsy describes sudden, natural, unexpected deaths, which may have a
cardiovascular or unknown etiology. A negative autopsy is declared when the death cannot be
attributed to any pathological or chemical changes in any of the examined systems (Semsarian &
Hamilton, 2012).
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Sudden death is any death occurring within an hour of the onset of symptoms or (if death
was unwitnessed) death after the individual was seen functioning normally within twenty-four
hours of being declared deceased (WHO, 2004). The National Association of Medical Examiners
(NAME) suggests that certain cases of sudden death be considered suspicious for a genetic
etiology, such as drownings, single motor vehicle accidents, unexplained seizure in a young
person, identified cardiomyopathy or aneurysm, sudden unexplained death in an individual with
a family history of heart disease or SUD, and any deaths that are sudden and with no clear cause
(Middleton et al., 2013). Included within the scope of testing available to the medical examiner
are molecular genetic tests in which preserved tissue or blood samples are sequenced to
determine if there are any variants in important genes which may be implicated in the sudden
death.
Life-threatening arrhythmias caused by channelopathies and cardiomyopathies can lead
to sudden death. Cardiac channelopathies cause disruptions in the typical flow of ions, leading to
an irregular electrochemical gradient in the heart (Fernández-Falgueras, Sarquella-Brugada,
Brugada, Brugada, & Campuzano, 2017). This may lead to abnormalities in the heartbeat,
causing malignant arrhythmias in anatomically normal hearts. Therefore, after a standard
autopsy, a channelopathy will not be identifiable without the utilization of molecular testing and
could result in a negative autopsy. Cardiomyopathies are often associated with structural changes
in the heart which interfere with the function of the cardiac muscles (Fernández-Falgueras et al.,
2017). However, some of these structural variations are subtle or localized and may be missed
upon physical examination. It is also possible that the defect is in a prodromal stage occurring
before signs of myocardial dysfunction are visible. Both of these conditions can cause the heart
to suddenly stop beating, cutting off the blood flow to the brain and other vital organs, resulting
in death without swift intervention.
According to the National Society of Genetic Counselors, the goal of post-mortem
genetic testing through molecular autopsy is to determine the cause of death and consequently
identify if blood relatives are at risk (NSGC, 2017). Many heritable arrhythmic and structural
syndromes are inherited in an autosomal dominant manner, meaning that if a decedent has a
pathogenic variant, there is a 50% chance any of their first-degree relatives also has this variant
(Bezzina, Lahrouchi, & Priori, 2015). This creates options for family members to be tested for
the familial variant, which can lead to increased surveillance to those at a high risk of having a
3

The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test
cardiac episode. Furthermore, according to the American College of Medical Genetics and
Genomics (ACMG), a definitive diagnosis through genetic testing provides the ability for
families to receive early intervention, independent of whether the affected family member
benefited directly from this diagnosis (Watson, 2015).
The research performed in the field of post-mortem genetic testing for cardiac genes has
identified a range of results, with some consistencies in findings as well as some incongruities
and limitations. Cardiac gene panels are usually targeted to specific loci likely to return results
(Semsarian & Hamilton, 2012) and provide insight into undiagnosed disease as a contributor to
the death. Studies have shown that 13% to 41% of the time a pathogenic or likely pathogenic
genetic change can be found through post-mortem testing in sudden unexplained death
(Campuzano et al., 2014; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al., 2016;
Tester, Medeiros-Domingo, Will, Haglund, & Ackerman, 2012). These numbers are in general
agreement with a National Association of Medical Examiners position statement suggesting that
genetic testing can help to identify the cause of cardiac death in either the deceased or the family
members as much as 40% of the time (Middleton et al., 2013). The ACMG asserts that the
clinical utility of medically actionable diagnoses which inform causality, prognosis, and
treatment are important to detect (Watson, 2015). Data reported by two different studies
provided evidence that a clinical diagnosis was able to be established in family members of a
decedent with a pathogenic variant in a cardiac gene approximately 12-13% of the time (Bagnall
et al., 2016; Lahrouchi et al., 2017). In studies examining genotype-phenotype correlations for
pathogenic variants, there is general agreement that adrenergic circumstances, including physical
activity, intense emotion, or stress, are often correlated with positive genetic test results
(Anastasakis et al., 2016; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al., 2016;
Tester et al., 2012). The same association is seen with personal and family histories of cardiac
events (Lahrouchi et al., 2017; Stattin et al., 2016; Tester et al., 2012). There is less agreement
when it comes to the effects of age (Campuzano et al., 2014; Tester et al., 2012), sex (Stattin et
al., 2016; Tester et al., 2012), and the comparative utility of testing for the different types of
cardiac problems (Anastasakis et al., 2016; Campuzano et al., 2014; Christiansen et al., 2016).
The available body of research is limited between races and ethnicities for the sudden cardiac
death population, and often the mechanism of defining race is poorly defined or absent, further
obscuring the data. One study claimed that the incidence of SCD is significantly high amongst all
4
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races, but accounts for overall deaths in 63.7% of Caucasians, 62% of African Americans, 60.5%
of Native Americans, and 55.2% of Asians (Zheng, Croft, Giles, & Mensah, 2001). Additionally,
Hispanics appeared to exhibit a lower proportion of cardiac deaths than non-Hispanics (Zheng et
al, 2001). The limited research on SCD risk associated with ethnicity highlights the necessity for
further study, especially as it relates to the diversity in New York City. These discrepancies may
exist because of the different ethnic diversity of populations being represented in each of these
studies; however, they may also exist because of some limitations in the literature as a whole.
There are multiple examples of limitations present in research on sudden cardiac death to
date. One such example is represented by the differences in classification of a negative autopsy
both between studies and within studies when autopsies were performed at multiple locations.
Additionally, for research performed prior to 2015, there was not yet standardization for variant
interpretation. These guidelines were released by The American College of Medical Genetics
(ACMG) in 2015 (Richards et al., 2015). Further limitations included the number and type of
genes being tested differing between studies, and the focus of much of this research on variably
defined age groups.
Individuals at risk for SCD are difficult to identify because often the first sign of cardiac
disease is sudden death, with no other symptoms or warning signs (Mozaffarian et al., 2016).
Moreover, due to the lack of autopsy findings after death, it can be difficult to diagnose these
cases, leaving many deaths unexplained. Therefore, it is of great benefit to recognize those who
carry a pathogenic gene variant in order to be able to enact preventative measures. To date, many
genetic variants have been identified that predispose an individual to SCD. Performing postmortem genetic testing on victims of SCD suspected to have a pathogenic variant not only has
implications for the family, but this type of testing can have broader impacts on public health
policies and healthcare as a whole. The characterization of these deaths can help inform
protocols, both for the management of other at-risk patients with these conditions and for
optimizing the approach to genetic testing of heritable cardiac conditions.
The current research surrounding sudden cardiac death is substantial but has the potential
for massive improvements. The goal of the present study performed in conjunction with the
Office of the Chief Medical Examiner (OCME) in New York City was to improve on this
research by studying the utility of a post-mortem 95-gene cardiac panel on individuals falling
into the SCD classification. Currently, the NYC OCME is the only medical examiner’s office in
5
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the country which performs in house genetic testing on autopsy samples; therefore, it is
particularly important to understand the effectiveness and utility of this particular panel when
examining the New York population. It is understood that NGS is useful for studying diseases
with large heterogeneity, such as cardiac disease, as long as a stringent filtration process is used
when approaching that the large variant dataset that accompanies with large panels (Farrugia,
Keyser, Hollard, Raul, Muller, & Ludes, 2015; Lin, Williams, Wang, Coetzee, Zhou, Eng,
Sampson, & Tang, 2017). The OCME developed a large custom NGS panel. As cardiac
conditions are known to be very heterogeneous, both in disease expression and in genetic origins,
the large panel was developed to identify the underlying genetic cause in many cases, while still
providing results associated with clinical actionability when pathogenic variants were found.
This study looks at all cases of sudden death, regardless of autopsy conclusion and age of
decedent. The 95-gene panel was used consistently for analysis of all cases and variant
interpretation was done by OCME genetics staff following ACMG guidelines for variant
interpretation (Richards et al., 2015; Yin, 2017). Through this analysis, we aim to describe the
genotype and phenotype of decedents with pathogenic changes to determine a profile of the
genetic SCD case, validate the specific gene panel in the New York population, and identify how
family members can influence and be influenced by testing.
Methods
Data Collection and Participants
Between October 2015 to February 2018, 267 deceased individuals whose deaths can be
classified as “sudden death” underwent gene testing through a customized 95 cardiac gene panel
at the New York City Office of the Chief Medical Examiner. Further data was collected on these
individuals from the OCME internal records including scene investigation by police and family
interview by a certified physician assistant, complete gross autopsy, neuropathologic and cardiac
pathology examinations, toxicological records, and microbiological tests and metabolic screens
in infants. Further information was also obtained from genetic reports and medical or hospital
records where available. Data collected for each case includes age, ethnicity, sex, genetic test
results, anatomical and heart findings, toxicology, circumstances of death (i.e. presenting
symptoms, activity at death, etc.), personal medical history, family medical history, and genetic
counseling services received (Table 1. Summary of Significant Personal and Family
Histories Collected). All demographics were obtained from internal OCME records, in which
6
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race and ethnicity were grouped together. As race is a social construct, henceforth we will refer
to these demographics collectively as ethnicity.
Of the study population, 13 cases were excluded from further analysis beyond
demographics, as autopsy information was unavailable due to objection by next of kin, autopsy
having been performed at another medical examiner’s office, or inaccessible autopsy report at
the time of data collection.
This study is not regulated by 45 CFR Part 46, Human Subjects Protection, because postmortem samples are not considered human subject and only cadaver specimens were used.
However, this research was approved by the Chief Medical Examiner and by the general counsel
at the OCME of NYC and deemed exempt from Institutional Review Board approval by a
committee at Sarah Lawrence College.
Genes
The panel analyzes 95 disease genes associated with cardiac channelopathies such as
Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular
tachycardia, as well as cardiomyopathies including hypertrophic cardiomyopathy,
arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and left ventricular
noncompaction cardiomyopathy. Most of the disorders on the panel are inherited in an autosomal
dominant fashion, but a few are inherited through an autosomal recessive pattern or an X-linked
pattern. A full list of genes and associated disorders is included (Figure 1. Results of the Next
Generation Sequencing Panel for Variants) (Tang, 2016).
Testing Methodology
The test was developed and performed in the Molecular Genetics Laboratory at the City
of New York Office of the Chief Medical Examiner and done through analysis of genomic DNA
from dry bloodstain cards or post-mortem tissue samples collected at the time of autopsy and
preserved in RNAlater. The institutional laboratory is accredited by The College of American
Pathologists (CAP), but the specific test has not been cleared by the FDA. The analysis
performed includes sequencing of both coding regions and splice sites of all 95 genes.
Oligonucleotide-based in-solution target capture (Haloplex Target Enrichment System, Agilent
Technologies) was performed, followed by next generation sequencing. The genomic reference
coordinate used is GRCh37/hg19. Illumina Miseq was used to perform primary sequencing data
analysis to generate a sequencing read. Secondary sequencing was then performed using
7
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NextGENe (SOFTGENETICS) and included the delivery of alignment data, variant
identification, and filtering the sequence by quality. Thirdly, variant classification was performed
by Geneticist Assistant (SOFTGENETICS) which accepts raw sequencing data and synthesizes
information from the following sources:
Functional Prediction information: SIFT, PolyPhen2, LRT, Mutation Taster, FATHMM,
CADD & Mutation Assessor
Disease association: ClinVar, OMIM & COSMIC
Conservation scores: PhyloP, GERP++, phastCons & SiPhy
Population frequencies: 1000 Genomes and Exome Variant Server
Further sequence analysis was performed to ensure quality, and when possible, follow up
confirmation with Sanger sequencing in regions with no coverage, low coverage (<30X), and
regions determined to have clinically significant alterations. The test detects >98% of
substitution variants (95% CI [98%, 99%]) (Tang, 2016).
Variant Interpretation
Evaluation of clinically significant variants was performed in accordance to guidelines
put forth by the American College of Medical Genetics and Genome (ACMG) and the
Association for Medical Pathology (Richards et al., 2015). The New York City Office of the
Medical Examiner is home to a molecular genetics laboratory, so all interpretation is done
internally. A bioinformatic pipeline, The Geneticist Assistant, is used to perform initial variant
interpretation from the raw data. Following this step, review of the data and further interpretation
and classification of reportable variants (pathogenic, likely pathogenic, variants of uncertain
significance) are done manually by the director of the laboratory and the genetic counselor. The
first step in classifying reportable variants is to determine if a sequence variant has been
previously reported. To do so, the variants are searched in disease databases such as the Human
Gene Mutation Database, ClinVar, and PubMed. The purpose of this is to determine if the
variant has been shown to have clinical relevance, if there is data from family or cohort studies,
or evidence of the deleterious or benign functionality of the variant. If the variant has never been
reported in the databases or in the literature, the evaluation of the variant consists of several
factors which contribute towards its classification. It is essential to assess the pattern of
inheritance, the type of variant (such as: loss of function, missense, in-frame insertions or
deletions), and its location in the protein or splice site of the gene. Additionally, databases such
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as Exome Aggregation Consortium (ExAC), 1000 genome, NHLBI Exome Sequencing Project
(ESP), The Genome Aggregation Database (gnomAD) are used to ascertain the minor allele
frequency of the variant in the general population, while computational tools such as Polyphen2,
Provean, or MutationTaster are utilized to determine the effect the variant may have on protein.
Finally, all relevant autopsy findings, medical history, and family history will be included to
determine the variant classification. All of the information gathered during this analysis will
provide a sense of how the variant may affect the individual (Tang, 2016).
Reporting
After all variants have been evaluated, each single variant is classified into one of five
categories which include: pathogenic, likely pathogenic, variant of uncertain significance (VUS),
likely benign, and benign. All pathogenic, likely pathogenic, and uncertain results are reported
because they are considered to be clinically significant and will be referred to as “reportable
results,” benign or likely benign variants are not reported. In this study, all pathogenic and likely
pathogenic variants were combined for analysis and will be referred to as “clinically actionable
variants”. These classifications were merged because they both routinely warrant
recommendations for clinical management and cascade genetic testing based on the variant
finding, as opposed to other variants such as negative or uncertain results, which are not
necessarily associated with an impact to clinical management or with recommendations to follow
up with clinical genetic services. Variant nomenclature follows guidelines provided by the
Human Genome Variant Society (HGVS). As the field of genetics and the study of new genes
and mechanisms are being updated all the time, all variant interpretations are subject to
modification and reclassification at any time. Any first-degree blood relatives of a decedent who
is found to carry a clinically significant variant may be recommended to receive clinical
evaluation and genetic counseling (Tang, 2016).
Test Benefits and Limitations
The benefit of this panel lies in the fact that it contains a large number of well understood
disease genes with associations to treatable conditions and uses Next Generation Sequencing
(NGS). NGS has proven to be a sensitive and specific valuable tool in post-mortem genetic
testing because of its high throughput and low cost, which also results in a stringent variant
filtration approach (Chanavat, Janin, & Millat, 2016; Farrugia et al, 2015). Also, using the
Haloplex Target Enrichment System, there is a low (2%) false positive rate due to technical
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limitations. However, analysis through NGS is also known to result in the accumulation of rare,
unknown variants (Farrugia et al, 2015). The limitations of performing this type of sequencing
include the exclusion of non-coding material, and the inability to detect inversions and deletions
or large copy number variants. Detection is also low in highly homologous or repeat regions.
Therefore, there could be a genetic alteration in one of the 95 genes that is outside of the region
that was tested on the panel but could still impact health and have implications in cause of death.
There could also be a genetic alteration in a gene that was not studied on the panel but plays a
role in cause of death. Other comparable commercial or clinical panels used for heritable cardiac
diseases may include different genes or testing methodologies. Finally, any post-mortem changes
to the quality of the blood sample collected during autopsy could impact results (Tang, 2016).
Statistical Analyses
The data was downloaded from Excel into SPSS version 24 for statistical analysis. Chisquare tests were used to investigate categorical predictors of a pathogenic or likely pathogenic
variant. P levels of p <0.05 was used to indicate statistical significance.
Results
The total sample (n = 254) was 64.2% male (n = 163) and 35.8% female (n = 91), and
40.8% Black (n = 102), 31.6% Hispanic (n = 79), 22.4% White (n = 56), and 5.2% Asian/Pacific
Islander (n = 13). The majority of cases consisted of those falling into the adult classification
(52.7%; n = 134). This was followed by the infant category (25.6%; n = 65), then young adults
(11.4%; n = 29), and finally, children (10.2%; n = 26). The mean age of the sample was 24 years,
while the median was 26.5 years. There was a standard deviation of 18.5 years. Of the total
sample (n=254), 22 individuals (9.4%) were exercising or exerting energy at the time of death,
129 individuals (55.4%) were at rest or sleeping at the time of death, 82 (35.2%) were engaged in
an activity other than rest/sleep or exercise/energy exertion at the time of death, and for 24 of the
individuals, activity at death is unknown (Table 2. Demographics and Clinically Actionable
Findings).
Genetic testing was performed and rendered 319 results in 51 of the 95 genes analyzed
(Figure 1. Results of the Next Generation Sequencing Panel for Variants). 60.5% (n=193) of
all results were reportable (pathogenic, likely pathogenic, variant of uncertain significance). In
39.5% (n = 126), no reportable variants were identified. Variants of uncertain significance (VUS)
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were found in the highest proportion of the sample (51.4%; n = 164). 9.1% of the sample (n=29)
had clinically actionable variants, 12 of the 29 were female and the remaining 17 were male. A
total of 48 subjects were reported to have greater than one variant detected by testing: 37 people
had 2 variants identified, 6 people had 3 variants identified, 4 people had 4 variants identified, 1
person had 5 variants identified. No individual was found to have more than one pathogenic or
likely pathogenic variant; however, 12 of the 29 cases with clinically actionable variants (41.4%)
were found to have one pathogenic/likely pathogenic variant in addition to at least one VUS. 58
of the 193 (30.1%) total reportable variants were novel, meaning that they had not previously
been identified in the population. Of these, 12 out of 58 (20.1%) were clinically actionable novel
variants.
Through Chi-square analysis, positive predictors of having a reportable genetic test result
were identified. Having a significant personal medical history was a positive predictor for
identifying a likely pathogenic or pathogenic variant on the 95-gene panel (χ2 = 13.82, df = 2, p
< 0.01). Cases with a pathogenic or likely pathogenic finding had significant personal histories
(17.4% versus 4.4%), while those without significant personal histories were more likely to have
VUS (54.4% versus 46.7%) and more likely to receive a negative result (41.4% versus 35.9 %)
(Figure 2. Significant personal medical history in those with clinically actionable results). In
addition, positive predictors of discovering a reportable variant included the presence of heart
findings (χ2 = 12.75, df = 2, p <0.01). More of those individuals with heart findings were found
to have clinically actionable variants (12.1% versus 3.1%), or VUS (53.4% versus 43.8%). There
were also more individuals with heart findings who had pathogenic or likely pathogenic results
(12.1% versus 3.1%) and more of those without heart findings received negative test results
(53.1% versus 34.4) (Figure 3. Heart findings found in those with genetic test results). A
significant family history (χ2 = 12.72, df = 2, p <0.01) was also determined to be associated with
reportable results. More individuals with a significant family history had VUS (54.1% versus
37.5%) or pathogenic/likely pathogenic (21.3% versus 6.3%) results found on genetic testing,
whereas more individuals (56.3%) without a significant family history were negative than those
with a significant family history (24.6 %).
When examining age distribution, there were significant associations based on age groups
(χ2 = 18.94, df = 6, p<0.01). Those in the 1 to 18 years of age category had the highest
percentage (63.9%) of variants of uncertain significance. Those under a year old had the highest
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percentage of negative results (53.9%), while those from 1 to 18 years had only 27.8% as
negative. Significant associations were also found between genetic test results and ethnicity (χ2 =
15.68, df = 6, p<0.05). VUS results were identified more frequently in individuals with
Asian/Pacific Island ancestry (76.2%) than for Blacks (59.4%), Hispanics (46.5%), Caucasians
(36.9%). Genetic test reports with negative results were more frequent in Caucasians (52.3%),
Hispanics (43.6%), and Blacks (32.8%) than for Asian/Pacific Islanders (14.3%). There were no
significant differences in the genetic test results based on sex (χ2 = 2.50, df =2, p = 0.29). Males
and females shared similar proportions of result classifications (Table 2. Demographics and
Clinically Actionable Findings).
There were no statistically significant differences in the results by type of activity at
death (χ2 = 2.96, df = 2, p= 0.23). Slightly more of those individuals exercising or exerting
energy (57.7%) or resting/sleeping (46.7%) had variants of uncertain significance. Additionally,
those individuals who received negative results were slightly more likely to have died while
resting or sleeping (47.7%) versus those were exercising or exerting energy at the time of death
(30.8%).
An examination of the genetic counseling encounters revealed that there were
recommendations in 116 cases for families to receive genetic counseling follow up. Of these,
only 25 families were known to have received genetic counseling. All cases who received
clinically actionable genetic test results (n = 29) were recommended for next of kin to seek
genetic counseling. In this subset, only 34.5% (n = 10) families were known to receive genetic
counseling. All 10 of these families were found to have significant family histories during the
course of the genetic counseling session. Of the remaining families, 18 did not have genetic
counseling, and it is unknown as to whether the last remaining family had genetic counseling.
Only 3 of the 18 families who did not have genetic counseling were reported to have significant
family histories by investigational personnel. 13 of the 18 families had unknown family histories,
and the remaining 2 families were reported to not have significant family histories.
Discussion
Implications
The present study examined the testing yield of post-mortem genetic testing in a sudden
death population that is representative of typical casework. Contrary to our heterogeneous
12
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sample, many previous studies have examined only sudden unexplained (or autopsy negative)
cases or cases with specific heart findings (i.e. cardiomyopathy) in their analysis. In this study,
29 clinically actionable results were detected in 29 of 254 individuals (11.4%) examined. The
findings resulted in a lower yield than found in previous research which reported yields from
13% up to as high as 40% (Campuzano et al., 2014; Christiansen et al., 2016; Lahrouchi et al.,
2017; Stattin et al., 2016; Tester et al., 2012). In other studies, the yield may have been higher
due to sample biases in selecting cases with specific heart findings or cases where no cause of
death could be determined. We attribute our lower yield to our heterogeneous sample. Using this
method, removing bias from our sample, there is inclusion of an increasing number of cases
where cardio-genetics may not have been a factor in death.
However, despite this lower yield, our results indicate that there is value in testing all
sudden death cases. In 11 cases out of the 29 (37.9%), there was an identified cause of death
determined irrespective of genetic results, which means that these cases would have been
overlooked in previous studies. This would mean that the at-risk family members eligible for
testing would also have been missed in protocols including only sudden unexplained deaths. This
information is useful because knowledge of one’s genetic results and therefore risk of cardiac
related deaths may inform lifestyle behavior or play a role in more complex diseases.
Additionally, these results bring to light the subjectivity in cause of death determination between
medical examiners and between institutions. This study highlights the benefit of doing postmortem genetic testing in individuals who have had sudden death, even for those in which the
cause of death may not, on autopsy, appear to be related to the cardiac system, such as cases of
acute drug overdose.
In addition to identifying heritable risks, this study identified 58 novel variants, which
broadens understanding of human variation and also identifies points of further research in
variant interpretation, as 46 of the 58 variants were classified as VUS. The findings of this study
further contribute to the growing body of literature as nearly half (n = 12; 41.4%) of the 29
clinically actionable cases were previously absent from the literature and OCME’s internal
database. The large proportion of VUS (51.4%; n = 164) in the total sample (n=254) is most
likely accounted for by the nature of NGS, revealing a large preponderance of rare missense
variants, as well as the generally large and heterogeneous characteristics of genes that influence
cardiac conditions.
13
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Of the 95 genes analyzed as a part of this study, we found variants in 51 (53.7%). We
theorize this is because of the breadth of genes we opted to include in our panel. In addition to
choosing major genes for conditions (such as KCNQ1), we also analyzed well understood genes
in which pathogenic variants are a rare cause of the cardiac conditions (such as NPPA). The
rationale of choosing such a large panel is that it is in the decedent's and their surviving family’s
best interest to test widely - including rare cardiac disease genes - to minimize overlooking a
heritable explanation for the sudden death. This is possible at the OCME, because the resources
and workforce are available to sequence, interpret, and make recommendations based on variants
found in any of the genes assessed, regardless of whether it is a major or minor disease-causing
gene. However, due to the low sample size of 254, we would not expect to have a high
frequency of variants in rare genes, explaining why in 46.3% (n = 44) of genes sequenced, no
reportable variants were discovered.
There were no significant differences found between groups when looking at sex, which
was surprising considering the much higher ratio of males to females in the total cohort.
However, the number of males to female in the clinically actionable result category was more
equivalent. In previous research, there have been variable conclusions regarding the effect of sex
on genetic test results. We theorize that due to the low yield of clinically actionable results in this
study, we did not have enough individuals in this group to identify trends in sex, if any do exist.
In other demographic categories, significant differences were observed between groups.
Though those who were reported as Asian/Pacific Islander made up a very small portion of the
cohort, at only 5.1%, these individuals had a significantly higher rate of variants of uncertain
significance, and lower rates of negative results than those of any other reported ethnicities
(Black, Hispanic, White). We attribute this level of uncertainty to the lack of robust population
databases for ethnicity matched controls. New York City is comprised of a diverse population,
and the need for broader studies on varying ethnic backgrounds is blatantly apparent.
There was a significantly higher number of VUS found in the child classification than in
any other age category. Classification of each variant was performed using ACMG guidelines,
which includes the phenotype of the patient as supporting evidence for pathogenicity. Young
individuals have the potential to be in a pre-symptomatic or prodromal stage, in which there is a
reduced chance for disease signs and symptoms (i.e. significant personal history, such as fainting
spells, or physical manifestations such as cardiomyopathy) prior to death. This reduces the
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amount of phenotypic information available during variant interpretation. This lack of potential
data supporting pathogenicity could have resulted in a higher number of VUS. The infant age
group represented the highest proportion of negative results, which may suggest other
mechanisms in infant death, including other heritable conditions not tested for on this cardiac
gene panel. In the future, it may be valuable to examine this subset of the sudden death
population with other gene panels for common infant onset conditions (such as seizure disorders)
to better characterize hereditary in deaths in individuals under one year of age.
The type of activity at death was not found to be a significant predictor of having a
reportable or clinically actionable result. This is inconsistent with previous literature, which
found correlations between adrenergic circumstances at time of death and pathogenic genetic test
results (Anastasakis et al., 2016; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al.,
2016; Tester et al., 2012). As previously discussed, some of these studies may have had sample
biases in selecting for those with certain findings or lack of findings on autopsy. The selected
findings could be correlated with genetic diseases that are known to be associated with sudden
death upon adrenergic exertion. The majority of those who were resting or sleeping at time of
death received a negative or VUS result. We propose that this could be because most individuals
under the age of 1, who received only negative or VUS results spend the majority of their day
sleeping or at rest and may comprise a large portion of this group. Another explanation for the
lack of significance in activity at time of death could be related to cases in which the death was
not observed. It is possible that when the death was not observed that the activity at time of death
could have been mislabeled as at rest.
The discovery of heart findings on autopsy was a positive predictor for having a
pathogenic or likely pathogenic genetic test result. It is reasonable to believe that this is due to
the effect that harmful variants in cardiac genes have on the cardiac system, resulting in signs of
disease. This group also exhibited more VUS as well. In the absence of other types of evidence
during variant interpretation, symptomology and phenotype are supportive of pathogenicity.
Therefore, it would make sense that these variants would not be classified as fully negative, and
also may not contain enough evidence to be labeled as pathogenic. Lack of heart findings on
autopsy was a positive predictor for a negative genetic test result. These cases could represent a
subset of the population who died for reasons other than cardiac problems.
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More of those who had a significant personal history were found to have pathogenic or
likely pathogenic findings, which is consistent with showing clinical symptoms of cardio-genetic
disorders. This supports the value of increasing awareness that referrals to genetics are necessary
in the presence of signs and symptoms that may be related to heritable cardiac conditions.
Variants were also more likely to be reported in individuals who had a family history remarkable
for cardiac-related incidents. Many cardio-genetic disorders are heritable, which is supported by
this evidence for family history of cardiac conditions. This also emphasizes the importance of
recognizing potential cardiac conditions present in families, as screening and treatment can be
effective in reducing mortality. Furthermore, many cardiovascular genetic diseases exhibit
variable expressivity and reduced penetrance, therefore it may be difficult to determine clinically
who is at risk without the assistance of molecular confirmation.
This study supported the value of genetic counseling sessions as a part of post-mortem
investigation in the presence of clinically actionable variants. This was demonstrated by the fact
that every case with clinically actionable findings that underwent genetic counseling was found
to have significant family histories (100%; n = 10). The cases that did not undergo genetic
counseling (n = 18) were only found to have significant family histories in 3 instances (16.7%).
The majority of the cases that did not receive genetic counseling were reported to have unknown
family histories, which reflects the absence of a fully comprehensive medical review (Figure 4.
Significant family medical history in those with reportable results). Collecting an accurate
family history is important for determining at-risk family members and elucidating segregation
in the family. Furthermore, we postulate that following molecular autopsy, there is psychosocial
benefit to receiving genetic counseling; however, in this study, not enough cases were seen by
genetic counselors to support this, and further study should be pursued.
Limitations
A primary limitation of this study was that it relied heavily on investigation and police
story reports to collect personal and historical narratives about the decedent. In these reports,
race and ethnicity were used interchangeably, which potentially confounds results on correlations
between genetic test results and ethnic backgrounds. It is unclear whether the results that we
obtained were meaningful based on ethnicity or whether they were a further perpetuation of race
as a social construct. Furthermore, investigation and police reports are variably comprehensive
regarding details such as personal medical history and family medical history. Genetic
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counselors are specially trained to collect personal and family medical history information. From
the results, it is clear that the genetic counseling encounters rendered more details in family
medical history. It is possible that in the investigation reports, pertinent information was missed.
Part of this lack in genetic counseling encounters is due to the fact that the NYC OCME did not
have a genetic counselor seeing families until September 7, 2016, as well as difficulties in next
of kin following up after the genetic results of the decedent are discovered. It is possible that if
more personal and family history was collected, different significant trends would have emerged.
As discussed previously, information on phenotype and medical history is integrated into variant
interpretation. Additionally, cascade testing in families contributes to interpretation, as through
tracking co-segregation of symptoms (or absences of symptoms) in relatives with variants there
can be a better understanding of whether a particular variant has deleterious effects. Therefore,
evidence supporting pathogenicity rather than supporting uncertainty, could have been missed.
Moreover, investigation and police story reports were also relied on for activity at time of death,
and as discussed previously, relying on next of kin reports in unobserved deaths may lead to
uncertainty in the results. Finally, due to the low number of genetic counseling encounters
observed, we were unable to perform meaningful statistics or study the clinical utility of
actionable results on family members.
Another limitation that exists is the examination of the relationship between heart
findings and genetic test results. Heart findings were defined as any change or abnormality of the
cardiac system found on autopsy. Therefore, in this study, individuals were labeled as having
heart findings if they had changes in the cardiac system relating to any cause, including
environmental. This limits the utility of the results found between heart findings and clinically
actionable test results, as some heart findings being examined are due to external or
environmental factors (i.e. necrosis of the cardiac muscle) or may be due to genetic conditions
not being examined on the 95-gene panel used in this study (i.e. congenital heart defects). The
purpose of examining heart findings is to determine if changes in the cardiac system are
significant predictors of clinically actionable genetic test results. Through being broad in the
definition of heart findings in this research, it is possible that a significant interaction was
missed. Future research would benefit from differentiating heart findings based on whether they
may be genetically derived (for example, cardiomyopathies detected on autopsy) or not, in order
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to assess true predictive value of heart findings on genetic testing as a part of post-mortem
analysis.
Conclusion
From these results, we are able to begin characterizing which individuals are most likely
to return a clinically actionable variant on a cardiac gene panel after a sudden death. Due to
limited resources available at many Medical Examiner’s offices, widespread testing on all
sudden death cases may not be feasible everywhere. However, this research supports the
importance of testing all cases, as 11 out of 29 at-risk families would have been overlooked if
their deceased relative was not tested due to having a cause of death after standard (nonmolecular) autopsy. Though at the NYC OCME there is an in-house testing laboratory where
extensive genetic sequencing and interpretation can take place, limitations in resource and
financial allocation at other institutions suggest that guidelines defining which decedents to test
to achieve the highest yield of clinically actionable variants may be necessary. Though more
research is required in a larger population to establish formal guidelines, this study strongly
supports the inclusion of remarkable family and personal medical history in providing a
molecular genetic test post-mortem.
Furthermore, this study provides support for the utility of genetic counseling involvement
in the process of post-mortem genetic testing, as it can elucidate medical histories more clearly
and also target psychosocial concerns, though this was not able to be addressed in the present
study. Future research on those who were able to receive genetic counseling should be
conducted, ideally once this subset represents a higher proportion of the sample. Perhaps
identifying the best time frame or method of communication for follow up with next of kin after
identification of clinically actionable results would assist in culminating a higher number of
genetic counseling visits.
Overall, due to the large yield of variants of uncertain significance, this study points out
that there is a need for more research and data collection on variants discovered through Next
Generation Sequencing in different populations. As more information is collected on variants in
healthy populations and affected individuals, variants of uncertain significance can be further
classified, which would be beneficial for underrepresented groups.
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Tables
Table 1. Summary of Significant Personal and Family Histories Collected
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Table 2. Demographics and Clinically Actionable Findings
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Figures
Figure 1. Results of the Next Generation Sequencing Panel for Variants

The number of VUS and clinically actionable findings in 51 genes on the panel are shown in the
bar graph. The 44 genes on the panel which had no results are listed above in the green circle.
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Figure 2. Significant personal medical history in those with clinically actionable findings

Significant personal history documented in those who had clinically actionable results.
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Figure 3. Heart findings based on genetic test findings

Prevalence of specific heart findings based on genetic test findings. Cases were classified for
inclusion by highest degree of pathogenicity. (a) Heart findings in cases with reportable variants
identified on NGS panel. Findings from cases with VUS findings were excluded if less than or
equal to 3 individuals had that particular finding. Four cases were excluded due to lack of
comprehensive cardiac examination due to organ donation. (b) Heart findings in cases with no
reportable variants found on NGS panel.

25

The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test
Figure 4. Significant family medical history in those with reportable results

Significant family history documented in those who had clinically actionable results. Note the
high frequency of unknowns in this category, theorized to be related to the low number of
genetic counseling appointments.
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